Jennifer is the Director of Biology at Chinook Therapeutics, a Vancouver-based biotechnology company developing precision medicines for rare kidney diseases. She has dedicated the last 20 years to preclinical drug discovery. Before being involved in the launch of Chinook, Jennifer spent five years at Inception Sciences, a Versant drug discovery engine, as a Senior Scientist II and then as an Assistant Director. Before that, she was a Research Scientist at Novo Nordisk in Seattle, where her work was focused on novel biologics for the treatment of autoimmune disorders. Early in her career, she was a Research Associate at AnorMED, where she was involved in the discovery and characterization of novel CXCR4 chemokine receptor antagonists including Mozobil and Mavorixafor.
Jennifer completed her Ph.D. in Biochemistry and Molecular Biology at The University of British Columbia in 2008. After her Ph.D. at UBC, she completed a postdoctoral research fellowship at Genentech in 2011. Her research involved examining the immunoregulatory roles of various cytokines with a focus on murine models of inflammatory bowel disease.